Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
SYNERGY PHARMACEUTICALS, INC. (SGYP)
|
Add to portfolio |
|
|
|
| Price: |
$0.01
| | Metrics |
| OS: |
248.0
|
M
| |
|
|
| Market cap: |
$2.23
|
M
| |
-10349
|
% ROIC
|
|
Net debt:
|
$73.9
|
M
| |
|
|
|
EV:
|
$76.2
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($135)
|
M
| |
|
|
|
EBIT
|
($136)
|
M
| |
|
|
| EPS |
($0.57)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 05/02/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 05/02/2019 |
8-K
| Bankruptcy or Receivership, Material Modifications to Rights of Security Holders, Changes in Control of Registrant, Departure... |
| 04/29/2019 |
8-K
| Bankruptcy or Receivership, Material Modifications to Rights of Security Holders, Regulation FD Disclosure, Other Events, Fin... |
| 04/12/2019 |
GN
| FINAL DEADLINE: Bronstein, Gewirtz & Grossman, LLC - UXIN, SGYP & MHLD |
| 04/02/2019 |
8-K
| Bankruptcy or Receivership, Financial Statements and Exhibits |
| 03/29/2019 |
GN
| Bronstein, Gewirtz & Grossman, LLC Class Action Update - UXIN, SGYP & MHLD |
| 03/21/2019 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and U...
|
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| Revenues | 16.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 13.4 | 9.6 |
| Revenue growth | | | | | -100.0% | -98.4% | 40.4% | 156.1% |
| Cost of goods sold | 8.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 26.8 | 19.1 |
| Gross profit | 8.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -13.4 | -9.6 |
| Gross margin | 47.6% | | | | | 0.0% | -100.0% | -100.0% |
| Selling, general and administrative | 181.9 | 58.2 | 21.8 | 11.0 | 11.7 | | | |
| Research and development | 48.3 | 87.1 | 78.0 | 83.3 | 50.6 | 29.3 | | |
| General and administrative | | | | | | 7.9 | 6.7 | 6.6 |
| EBIT | -222.2 | -145.3 | -99.8 | -94.3 | -62.3 | -37.2 | -20.2 | -16.1 |
| EBIT margin | -1321.0% | | | | | -17080.3% | -150.3% | -168.6% |
| Pre-tax income | -224.3 | -198.6 | -117.5 | -95.7 | -62.1 | -39.4 | -14.5 | -15.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -224.3 | -198.6 | -117.5 | -95.7 | -62.1 | -39.4 | -14.5 | -15.2 |
| Net margin | -1333.8% | | | | | -18093.6% | -107.8% | -159.2% |
| |
| Diluted EPS | ($1.00) | ($1.21) | ($1.11) | ($1.02) | ($0.73) | ($0.64) | ($0.30) | ($0.34) |
| Shares outstanding (diluted) | 225.4 | 164.4 | 105.6 | 94.3 | 85.2 | 61.7 | 47.6 | 44.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|